

Value of Medicines: Psoriasis

About the Disease

Psoriasis is a chronic, immune-mediated inflammatory skin disease, affecting the skin and other parts of the body. It affects approximately 2 to 3 percent of people worldwide, including 7.4 million people in the United States.¹


The most common form is plaque psoriasis, which affects about 80 – 90 percent of people who have the condition.² Of those, as many as 20 percent have moderate-to-severe chronic plaque psoriasis.³ Some people with plaque psoriasis also have psoriatic arthritis, a form of arthritis characterized by joint pain, stiffness and swelling. It can affect any part of the body and can be a debilitating illness.⁴ Psoriasis has a strong genetic correlation, as studies reveal 36 genetic markers associated with the disease.⁵



Adopted from Vanderpuye-Orgle J., Y. Zhao, J. Lu, A. Shrestha, A. Sexton, S. Seabury, M. Lebwohl, (2015) Evaluating the economic burden of psoriasis in the United States, JAm Acad Dermatol , V72 (6), pg 961–967,e5

Treating Psoriasis

Topical agents (e.g., steroidal creams, ointments) are considered to be the first-line treatments for mild symptoms of the disease. For patients with greater percent body surface area of involvement or with a condition that has significant quality of life impact, systemic therapy (drugs taken within the body) and/or phototherapy is prescribed.⁶ Systemic medication for psoriasis can be broadly divided into small molecules, which are usually given orally, and large molecules (biologics), that must be delivered by injection or infusion. These medicines can be used as single agents (monotherapy), combined with other drugs (for more severe cases), or even used with phototherapy.⁷ Systemic medications may include general anti-inflammatory drugs, or the newer immunosuppressant drugs that target specific pathways involved in the pathological immune response that causes psoriasis.



Adopted from Bringing Psoriasis Into Light (09 May 2014) www.ifpma.org

KEY TAKEAWAYS

2 to 3 percent of the world's population (over 125 million people) including over 7.4 million in the U.S. have psoriasis.¹

Psoriasis has a strong genetic correlation, as studies reveal 36 genetic markers associated with the disease.⁵

The annual U.S. cost of psoriasis amounted to approximately \$112 billion in 2013.⁹


Almost 75 percent of patients surveyed believed that psoriasis had a moderate-to-large negative impact on their quality of life.⁷


Studies have demonstrated both cost effectiveness and quality of life gains from psoriasis treatments.^{16, 21}


Significant progress in drug development for the treatment of psoriasis has been made in recent years.²²

Health Burden

While psoriasis was originally believed to be, and is often thought of as, a skin disease, scientific evidence tells us that psoriasis is associated with systemic (whole body) inflammation, and that patients with the disease are at a significantly increased risk for other comorbidities, including (but not limited to) some forms of cancer, heart disease, Crohn's Disease, depression, and diabetes.⁸

 **46%** Patients have an increased risk for type 2 diabetes, and those with severe psoriasis were 46 percent more likely to have type 2 diabetes.

 **58%** People with severe psoriasis are 58 percent more likely to have a major cardiac event and 43 percent more likely to have a stroke.

 **25%** Approximately 25 percent of patients report psychological comorbidities such as stress, anxiety and depression.

Adopted from Bringing Psoriasis Into Light (09 May 2014) www.ifpma.org

Psoriasis can have a significant negative impact on a patients' quality of life. A survey by the National Psoriasis Foundation in the U.S. found that almost 75 percent of surveyed patients believed that psoriasis had moderate-to-large negative impact on their quality of life, which included alterations in their daily activities.⁹ One common ailment associated with plaque psoriasis is the symptom of itching, which, according to some patients, has been compared to being bitten by fire ants.¹⁰ Furthermore, due to the scaly rash that often appears on the skin, many patients have difficulties in social interactions and face emotional stress, which in turn can influence the development and exacerbation of psoriasis outbreaks.¹¹ Psoriasis patients are more likely to suffer from depression and psychological conditions. In fact, one recent study indicated that there is a 44 percent increased risk of suicidal thoughts, attempts, or completed suicide in psoriasis patients compared to the general population.¹²

OF ALL PSORIASIS PATIENTS SURVEYED



consider psoriasis to have a major effect on the quality of life



feel stigmatized



report significant psychiatric symptoms



report lower self-confidence from their disease

Adopted from Bringing Psoriasis Into Light (09 May 2014) www.ifpma.org

Economic Burden

Psoriasis exerts a significant economic cost for both the patient and society. In a recent study published in *The Journal of the American Medical Association*, the annual direct and indirect cost of psoriasis amounted to approximately \$112 billion in 2013, which included up to \$63.2 billion in direct costs (expenses from the primary disease) and \$35.4 billion in indirect costs (determined by loss of work productivity), and medical comorbidities (conditions associated with psoriasis) were estimated to be \$36.4 billion.¹¹ In a survey in the U.S. using data from 2003 to 2011, 92% of patients with (mainly) moderate or severe psoriasis said that their psoriasis or their psoriatic arthritis was the only reason for not working.¹³ The findings from these U.S. studies showing the high burden of indirect costs are consistent with other countries, including Germany, where average annual costs for psoriatic arthritis patients increased from €3,150 per patient, to approximately €5,500–11,075 per patient, when indirect costs are also considered.¹⁴ Additionally, based on a systematic literature review on the economic burden of psoriasis in 11 countries, costs associated with psoriasis were comparable to other costly conditions such as pancreatic cancer, melanoma, prostate cancer and asthma.¹⁵

Value of Medicines in Psoriasis

Improving Outcomes through Innovation

The treatment of psoriasis and psoriatic arthritis has evolved over the past decade due to the advent of biologic therapies designed to target specific components of the immune system. Due to advances in our understanding of the immune system, these newer agents have been more effective and can improve the quality of life for millions of people who suffer from the chronic condition.^{16, 17} These newer therapies represent a major technological improvement over traditional immunosuppressive medications, as many of these treatments have been shown to reduce psoriasis activity by as much as 75 percent in clinical trials.¹⁸ In particular, for patients with extensive or recalcitrant disease, the management of psoriasis has been improved on account of these newer agents.¹⁹

Improvements in Health Care Resource Utilization (HRU)

Health care resource utilization refers to the consumer use of health care resources and services, and reflects the way patients interact with health care providers. Patterns of utilization help to describe the health status of the population and availability of resources.²⁰ Findings from studies measuring this outcome for plaque psoriasis and psoriatic arthritis patients have shown significantly reduced resource utilization in recent years on account of newer therapies.^{21, 22}

Offsetting Health Care Costs

Pharmacoeconomic studies have identified positive economic benefits and offsetting health care costs as a result of some psoriasis treatments. One study published in the *British Journal of Dermatology* showed that hospitalizations costs were greater than drug costs for moderate-to-severe plaque-type psoriasis.²³ Additionally, recent studies comparing older inpatient-based care with the outpatient-based care that new drugs have allowed concluded that inpatient therapy caused significantly higher direct medical, indirect and total annual costs than outpatient treatment.²⁴

Work Productivity Gains

One study recently published in *BMC Dermatology* examined the efficacy of one systemic treatment in patients with moderate-to-severe plaque psoriasis and psoriatic arthritis on employment status, job duties and sick days among this patient population. The study found that there was a decrease (from 17–23 percent to 5–8 percent) in the number of patients whose job responsibilities had to change due to symptoms of their psoriatic arthritis. Similar results were seen with job responsibility changes due to symptoms of psoriasis (from 11–14 percent to 4 percent). There was also a greater than 47 percent reduction in sick days after 12 weeks of treatment.²⁵

COSTS SAVED THROUGH REDUCED HOSPITALIZATIONS WERE GREATER THAN DRUG-RELATED COSTS



For some available treatments of moderate-to-severe psoriasis

Adopted from: Sitzo, S, Bansback, N., Feldman, S. R., Willian, M. K., Ants, A. H. (2009). Economic evaluation of systemic therapies for moderate to severe psoriasis. *British Journal of Dermatology*, 160, 6, 1264-72.

Under-Treatment Opportunity

While guidelines typically state that patients with moderate-to-severe psoriasis are candidates for systemic therapy, many adult plaque psoriasis patients appear to be undertreated, with approximately 30 percent of treated moderate patients and 22 percent of treated severe patients receiving only topical therapy in the U.S. Moreover, in the same study, it was discovered that a large percentage of patients were not treated at all, including those with mild psoriasis (ranging from 36.6 to 49.2 percent), moderate psoriasis (ranging from 23.6 to 35.5 percent), and severe psoriasis (ranging from 9.4 to 29.7 percent).²⁶ Based on a recent survey, over 85 percent of psoriasis (and psoriatic arthritis) patients surveyed felt that better therapies are needed.²⁷

**MORE THAN
85%
OF PATIENTS*
SURVEYED FEEL
BETTER THERAPIES
ARE NEEDED**

*Surveyed psoriasis and arthritic psoriasis patients.

Adopted from: Lebwoh M., H. Herve, J. Barker, G. Girolomoni, A. Kavanaugh, R.G. Langely, C. F. Paul, L. Puig, K. Reich, P. C. M. van de Kerkhof, (2013) Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. *Journal of the American Academy of Dermatology*, V7(5), Pg 871-881.

Fortunately, significant progress in drug development for the treatment of psoriasis continues. Precision medicine is a developing method of care in which medical decisions and therapies are tailored to the individual patient based upon the patient's genetics and other molecular or cellular analysis. Knowledge gained from the study of disease and drug responses, and the development of diagnostic tests, should lead to the development of refined treatment plans, influencing the prescribing of therapies that are most likely to be safe and efficacious for a given patient.²⁸ Today, there have never been more options for treating moderate-to-severe psoriasis, and the quality of clinical data supporting conventional drugs continues to improve.

References

1. Vanderpuye-Orgle J., Y. Zhao, J. Lu, A. Shrestha, A. Sexton, S. Seabury, M. Lebwohl. (2015) Evaluating the economic burden of psoriasis in the United States. *J Am Acad Dermatol* . V72 (6), pg 961–967.e5
2. American Academy of Dermatology. (Aug 2015) Viewed online at <https://www.aad.org/media-resources/stats-and-facts/conditions/psoriasis>
3. Menter A, Gottlieb A, Feldman SR, et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1, Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008;58(5):826-50.
4. About psoriatic arthritis. (August 2015) National Psoriasis Foundation. Viewed online at <https://www.psoriasis.org/page.aspx?pid=1336>
5. Tsoi L, C., Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., ...Worthington, J. (2012). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. *Nature Genetics*, 44, 1341-8. Doi: 10.1038/ng.2467.
6. Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., ...Bhushan, R. (2009). Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4, Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*, 61, 3, 451–85.
7. Strober, B. E., Siu, K., Menon, K. (2006). Conventional systemic agents for psoriasis. A systematic review. *J Rheumatol*, 33, 7, 1442–6.
8. Comorbidities associated with psoriatic disease. National Psoriasis Foundation. Viewed online at <https://www.psoriasis.org/about-psoriasis/related-conditions> (August 2015)
9. Health and Quality of Life Outcomes (2006) Quality of Life in Patients with Psoriasis. 4: 35. doi: 10.1186/1477-7525-4-35
10. Managing Itch. National Psoriasis Foundation (August 2015) Viewed online at <https://www.psoriasis.org/life-with-psoriasis/managing-itch>
11. Brezinski, E. A., Jaskaran, S. D., and Armstrong, A. W. (2015). Economic Burden of Psoriasis in the United States: A Systematic Review. *JAMA Dermatol*. Doi: 10.1001/jamadermatol.2014.3593
12. International Federation of Pharmaceutical Manufacturers & Associations – Infographic (May 2014) Viewed online at http://www.ifpma.org/fileadmin/content/Publication/2014/IFPMA_Psoriasis_Infographic_May2014.pdf
13. Armstrong AW, Schupp C, Wu J, Bebo B, Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011. Hamblin M, editor. *PLoS ONE*. 2012 Dec 28;7(12):e52935
14. Huscher D, Merkesdal S, Thiele K, Ziedler H, Schneider M, Zink A. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Ann Rheum Dis* 2006; 65: 1175-83
15. S Feldman, C Burudpakdee, S Gala, M Nanawaty, U Mallya. (2014) The economic burden of psoriasis: a systematic literature review. *Expert Review of Pharmacoeconomics & Outcomes Research* Vol. 14, Issue 5, 2014
16. Mrowietz U, Macheleidt O, Eicke C. (2011) Effective treatment and improvement of quality of life in patients with scalp psoriasis by topical use of calcipotriol/betamethasone: results. *J Dtsch Dermatol Ges*. 2011 Oct;9(10):825-31
17. Salek MS, Finlay AY, Lewis JJ, Sumner MI (2004) Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporine. *Qual Life Res*. 2004 Feb;13(1):91-5
18. Psoriasis Treatment: What's in the Future? Viewed online at <http://www.webmd.com/skin-problems-and-treatments/psoriasis/research?page=2> (Aug. 2015)
19. S. Feldman Treatment of Psoriasis. UpToDate. (Jul 2015) Viewed online at <http://www.uptodate.com/contents/treatment-of-psoriasis>.
20. Health Resource Utilization – Overview. Health Trends in Hawai'i: A Profile of the Healthcare System. Viewed online at http://www.healthtrends.org/healthutilize_overview.aspx (Aug 2015)
21. Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Woolley JM, Xia HA, Chiou CF, Stevens SR. (2007) Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. *J Drugs Dermatol* 2007 Mar;6(3):299-306
22. Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M. (2012) Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. *Applied Health Economics and Health Policy* 2012 Vol 10, Issue 5, pp 343 2014, 14:14
23. Sitzo, S, Bansback, N., Feldman, S. R., Willian, M. K., Anis, A. H. (2009). Economic evaluation of systemic therapies for moderate to severe psoriasis. *British Journal of Dermatology*, 160, 6, 1264-72. Doi: 10.1111/j.1365-2133.2008.08962.x
24. Steinke SIB, Peitsch WK, Ludwig A, Goebeler M. Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy. *PLoS One*. 2013; 8(10): e78152.
25. Boggs, R.L, et al Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment. *BMC Dermatology* 2014, 14:14
26. Armstrong, A. Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States. Findings From the National Psoriasis Foundation Surveys, 2003-2011. *JAMA Dermatology*. 2013; 5264.
27. Lebwoh M., H. Herve, J. Barker, G. Girolomoni, A. Kavanaugh... M, van de Kerkhof. (2013) Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. *Journal of the American Academy of Dermatology*. V7(5). Pg 871-881.
28. Menter, M. A, and Griffiths, C. E. (2015). Psoriasis: the future. *Dermatol Clin*, 33, 1, 161–6. Doi: 10.1016/j.det.2014.09.012.